<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4387">
  <stage>Registered</stage>
  <submitdate>3/04/2014</submitdate>
  <approvaldate>3/04/2014</approvaldate>
  <nctid>NCT02107313</nctid>
  <trial_identification>
    <studytitle>Phase 1 Study to Determine the Effects of Food on the Pharmacokinetic Profile of PBT2</studytitle>
    <scientifictitle>A Phase 1, Single Centre, Randomised, 2 Period Crossover Study to Determine the Effect of Food on the Pharmacokinetic Profile of a Single Dose of PBT2 Administered Orally to Healthy Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>PBT2-103</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy Volunteers</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Fed Cohort PBT2
Treatment: drugs - Fasted Cohort PBT2

Other: Fed Cohort - PBT2 250 mg is administered orally following a high fat breakfast

Other: Fasted Cohort - PBT2 250 mg is administered orally following a 10 hour period of fasting


Treatment: drugs: Fed Cohort PBT2
PBT2 250 mg is administered orally following a period of fasting for 10 hours and a high fat breakfast.

Treatment: drugs: Fasted Cohort PBT2
PBT2 250 mg is administered orally after a period of fasting of 10 hours and without food

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Area Under the Concentration-Time Curve (AUC 0-t)</outcome>
      <timepoint>prior to the initial doses on day 1 and 8 and then 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 5, 5.5, 6, 8,10,12,16, 24, 30, 36, 48 hours post each dose</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and Tolerability of PBT2 in Healthy Volunteers Measured by the Number of Participants Reporting at Least One Treatment Emergent Adverse Events</outcome>
      <timepoint>Up to 15 days after the first dose of PBT2</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy male or females with a BMI between 19 and 30kg/m2

          -  No clinically significant abnormalities</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Exposure to medications/drugs that interfere with metabolism of PBT2 including drugs
             that inhibit or induce CYP1A2)

          -  Use of caffeine-containing beverages, supplements or alcohol within 72 hours of study
             entry

          -  Significant history of depression or other psychiatric illness

          -  Surgical or medical conditions which could significantly alter drug absorption,
             distribution, metabolism or excretion

          -  unable to swallow capsules</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Basic Science</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>18</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Centre for Clinical Studies - Nucleus Network - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Prana Biotechnology Limited</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is designed to determine the pharmacokinetic (PK) profile of a single oral dose of
      PBT2 administered to healthy volunteers in the presence and absence of food.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02107313</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Caroline Herd</name>
      <address>Prana Biotechnology</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>